Published on
November 10, 2020
- 21:00 GMT
Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH
FDA confirms that a single Phase III clinical trial may be adequate for submitting U.S. marketing authorization application Interim histology analysis may serve as the basis for seeking FDA accelerated approval Inventiva confirms planned initiation of …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
...
